BACKGROUND: Docetaxel (DOC) is inactivated by CYP3A4, high expression of which in tumor tissue might serve as a resistance mechanism. In the present study, the CYP3A4 protein level in breast cancers was determined by immunohistochemistry, and its relationship with the response to DOC treatment was studied. MATERIALS AND METHODS: Thirty-one patients with locally advanced (n = 21) or recurrent (n = 10) breast cancers underwent tumor biopsy, followed by DOC treatment (60 mg/m2 q3w). Expression of CYP3A4 was studied by immunohistochemistry. RESULTS: Patients with CYP3A4 negative tumors (n = 15) by immunohistochemistry showed a significantly (P < 0.01) higher response rate (67%) to DOC treatment than those with CYP3A4 positive tumors (n = 16, 19%). The positive predictive value, negative predictive value, and diagnostic accuracy of CYP3A4 expression by immunohistochemistry in the prediction of response to DOC were 67%, 81%, and 74%, respectively. CONCLUSION: Immunohistochemical analysis of CYP3A4 expression in tumor cells might be clinically useful in the prediction of tumor response to DOC.
BACKGROUND:Docetaxel (DOC) is inactivated by CYP3A4, high expression of which in tumor tissue might serve as a resistance mechanism. In the present study, the CYP3A4 protein level in breast cancers was determined by immunohistochemistry, and its relationship with the response to DOC treatment was studied. MATERIALS AND METHODS: Thirty-one patients with locally advanced (n = 21) or recurrent (n = 10) breast cancers underwent tumor biopsy, followed by DOC treatment (60 mg/m2 q3w). Expression of CYP3A4 was studied by immunohistochemistry. RESULTS:Patients with CYP3A4 negative tumors (n = 15) by immunohistochemistry showed a significantly (P < 0.01) higher response rate (67%) to DOC treatment than those with CYP3A4 positive tumors (n = 16, 19%). The positive predictive value, negative predictive value, and diagnostic accuracy of CYP3A4 expression by immunohistochemistry in the prediction of response to DOC were 67%, 81%, and 74%, respectively. CONCLUSION: Immunohistochemical analysis of CYP3A4 expression in tumor cells might be clinically useful in the prediction of tumor response to DOC.
Authors: Lina Schiffer; Lise Barnard; Elizabeth S Baranowski; Lorna C Gilligan; Angela E Taylor; Wiebke Arlt; Cedric H L Shackleton; Karl-Heinz Storbeck Journal: J Steroid Biochem Mol Biol Date: 2019-07-27 Impact factor: 4.292
Authors: Cristina Rodriguez-Antona; Alvin Gomez; Maria Karlgren; Sarah C Sim; Magnus Ingelman-Sundberg Journal: Hum Genet Date: 2009-10-08 Impact factor: 4.132
Authors: Yu-Ting Chang; Daniela Hernandez; Salvador Alonso; Minling Gao; Meng Su; Gabriel Ghiaur; Mark J Levis; Richard J Jones Journal: Blood Adv Date: 2019-03-26
Authors: Martina Baur; Allan T van Oosterom; Véronique Diéras; Michele Tubiana-Hulin; R Charles Coombes; Thomas Hatschek; Michael Murawsky; May Klink-Alakl; Marcus Hudec; Christian Dittrich Journal: J Cancer Res Clin Oncol Date: 2007-07-17 Impact factor: 4.553
Authors: J Kurashige; M Watanabe; M Iwatsuki; K Kinoshita; S Saito; Y Nagai; T Ishimoto; Y Baba; K Mimori; H Baba Journal: Br J Cancer Date: 2012-09-06 Impact factor: 7.640